scPharmaceuticals Receives Notice of Allowances of Multiple US Patent Applications Covering SCP-111
BURLINGTON, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through pa...
What is the potential impact on the company's pipeline valuation if SCP-111 proves successful and funds further development projects?
Are there any regulatory or reimbursement hurdles specific to the SCP-111 formulation that could impact its commercial rollout?
How might the patent allowances influence analyst coverage, target price revisions, or institutional sentiment toward SCPH?
10 days ago